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Background: Additional treatment with a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) before IVF-ET
(ultralong GnRHa therapy) has been reported to improve the outcome of IVF-ET in endometriosis patients. However,
the mechanism of ultralong GnRHa therapy is unclear. It is suggested that inflammatory cytokines and oxidative
stress contribute to infertility in endometriosis patients. Therefore, in order to search a possible mechanism of
ultralong GnRHa therapy, we investigated the effect of ultralong GnRHa therapy on intrafollicular concentrations of
tumor necrosis factor alpha (TNFα), oxidative stress markers, and antioxidants in patients with endometriosis.
Methods: Twenty-three infertile women with Stage III or IV endometriosis were recruited for this study. Eleven
patients received three courses of GnRHa (1.8 mg s.c. every 28 days), followed by a standard controlled ovarian
hyperstimulation (COH) for IVF-ET (ultralong group). The other 12 patients received a standard COH with mid-luteal
phase GnRHa down-regulation (control group). The numbers of matured follicles and retrieved oocytes, fertilization
rates, implantation rates, clinical pregnancy rate, and intrafollicular concentrations of TNFα, 8-hydroxy-2’-deoxyguanosine
(8-OHdG) and hexanoyl-lysine adduct (HEL) as oxidative stress markers, and melatonin and Cu,Zu-superoxide dismutase
(Cu,Zn-SOD) as antioxidants were compared between the two groups.
Results: The numbers of mature follicles and retrieved oocytes, and fertilization rates did not differ between the two
groups. Implantation rates and pregnancy rates tended to be higher in the ultralong group (21.4% and 27.3%,
respectively) compared with the control group (8.3% and 8.3%, respectively). TNFα concentrations in the follicular fluid
were significantly lower in the ultralong group (5.8 ± 3.2 pg/ml) than those in the control group (10.6 ± 3.2 pg/ml).
Follicular concentrations of 8-OHdG concentrations were significantly lower in the ultralong group (5.7 ± 1.6 ng/ml) than
those in the control group (6.6 ± 1.5 ng/ml), while melatonin concentrations were significantly higher in the ultralong
group (139 ± 46 pg/ml) compared with the control group (86 ± 27 pg/ml).
Conclusions: Ultralong GnRHa therapy reduces the detrimental effects of cytotoxic cytokines and oxidative stress in the
ovary in patients with endometriosis.
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Endometriosis is considered to be the most intractable
cause of female infertility [1,2]. Possible causes of the in-
fertility include poor quality of oocytes and embryos [3],
impaired fertilization [4,5], and impaired implantation
[6], each of which can be induced by inflammation and* Correspondence: sugino@yamaguchi-u.ac.jp
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unless otherwise stated.oxidative stress in the pelvic cavity [7-9]. In fact, increased
levels of inflammatory cytokines such as interleukin-6
(IL-6), interleukin-8 (IL-8), and tumor necrosis factor-
alpha (TNFα) have been observed in the peritoneal fluid
in patients with endometriosis [10]. TNFα, which is pro-
duced by activated macrophages and NK cells, is a key
molecule in endometriosis. TNFα in the peritoneal cavity
impairs oocytes and embryos by its cytotoxicity [11,12].
TNFα also increases prostaglandin production by endo-
metrial epithelial cells, which in turn initiates a surge ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This surge of inflammatory cytokines has been proposed
as a cause of endometriosis-related implantation failure
[13,14]. In addition, endometriosis patients showed high
concentrations of TNFα in ovarian follicular fluids,
which is associated with poor oocyte quality or impaired
fertilization [11].
Chronic inflammation in the pelvic cavity of endo-
metriosis patients also induces oxidative stress in both
the pelvic cavity and reproductive organs. Increased
and activated macrophages and polymorphonuclear
leucocytes in the peritoneal fluid produce large amounts of
reactive oxygen species (ROS) in patients with endometri-
osis [15]. Oxidative stress levels in the ovarian follicular
fluid are higher in patients with endometriosis than in other
infertility patients without endometriosis [16]. ROS produc-
tion by endometrium is increased in endometriosis patients
[17]. Oxidative stress causes detrimental effects on cells
through lipid peroxidation, protein oxidation, and DNA
damage. Oxidative stress in the peritoneal cavity is one
of the causes of endometriosis-associated infertility [8].
Oxidative stress reduces oocyte quality [18-20] and im-
pairs endometrial receptivity [21]. Together, these find-
ings strongly suggest that oxidative stress contributes to
infertility in endometriosis patients.
The pregnancy outcomes of endometriosis patients who
undergo in vitro fertilization and embryo transfer (IVF-ET)
are generally poor [22], and there are no effective treat-
ments for endometriosis-related infertility. Additional treat-
ment with a gonadotropin-releasing hormone (GnRH)
agonist (GnRHa) before IVF-ET (ultralong GnRHa therapy)
improved the outcome of IVF-ET in endometriosis pa-
tients, as shown by increased numbers of retrieved oocytes
and transferred embryos, and higher implantation and
pregnancy rates [23-25]. However, the mechanism of
ultralong GnRHa therapy is unclear. Therefore, we investi-
gated the concentrations of TNFα and oxidative stress in
ovarian follicular fluids to see if they can shed light on the
mechanism by which ultralong GnRHa therapy improves
the IVF-ET outcome in endometriosis patients.
Materials and methods
Patients and clinical study
This study was reviewed and approved by the Institutional
Review Board of Yamaguchi University Graduate School of
Medicine. Informed consent was obtained from all the
patients in this study. Twenty-three infertile female pa-
tients with endometriosis were recruited for this study.
The mean age ± S.D. of the patients was 34.0 ± 3.3 yr.
with a range of 28–40 yr. Diagnosis of endometriosis
was confirmed by laparoscopy, laparotomy, or transvaginal
aspiration of the ovarian endometrial cyst. Severity of
endometriosis was scored according to the four-stage clas-
sification of the revised American Society for ReproductiveMedicine (rASRM) score, and all patients had stage III or
IV endometriosis. Patients were nonsmokers and free from
major medical illness including hypertension; all were inter-
ested in becoming pregnant. Patients were excluded if they
had myoma, adenomyosis, a congenital uterine anomaly,
or if they used any kind of sex-steroidal agent including
estrogens, progesterone, androgens, and OC.
Eleven patients received three courses of GnRHa
(1.8 mg s.c. every 28 days) (buserelin acetate, Suprecur;
Mochida Pharmaceutical Co. Ltd., Tokyo, Japan), followed
by a standard controlled ovarian hyperstimulation (COH)
for IVF-ET (ultralong group). Withdrawal bleeding was
induced using estrogen (Premarin: conjugated estrogens
tablets, Pfizer Pharmaceutical Co. Ltd., Japan) and proges-
terone (Duphaston: dydrogesterone tablets, Daiichi-Sankyo
Co. Ltd., Japan) before COH. COH was initiated from the
2nd day of the IVF-ET cycle by injection of 225 IU FSH
(Folyrmon P; Fuji Pharmaceutical Co. Ltd., Tokyo, Japan)
for 3 days, followed by a daily injection of 150 IU HMG
(HMG F; Fuji Pharmaceutical Co. Ltd., Tokyo, Japan). Nasal
spray GnRHa (900 μg/day buserelin acetate, Suprecur;
Mochida Pharmaceutical) was also given from the 2nd
day of the IVF-ET cycle to continuously suppress pituit-
ary gonadotropin secretion until the injection of HCG
(HCG Mochida 10,000 IU; Mochida Pharmaceutical) for
ovulation induction. Ultralong group included one case
with a male factor.
Twelve patients received a standard COH with mid-
luteal phase GnRHa down-regulation (control group).
In the control group, nasal spray GnRHa (900 μg/day)
was given from the mid-luteal phase in the previous
cycle to the time of HCG injection for ovulation induction
of the IVF-ET cycle. COH was given in a manner similar
to the ultralong group described above.
When leading follicles reached 18 mm or more, HCG
was injected for ovulation induction. Oocyte retrieval
was carried out 35 h after HCG injection. Each mature
follicle (more than 18 mm in diameter) was aspirated
separately and the follicular fluid containing the oocyte
was collected. Immediately after removal of the oocyte,
each of the follicular fluids was centrifuged at 300 x g for
15 min to remove cellular components. The supernatant
from each follicle was mixed in each patient and was kept
at –80C until assayed. The numbers of matured follicles,
retrieved oocytes and fertilized oocytes, and fertilization
rates, implantation rates, and clinical pregnancy rates
were compared between the two groups. Concentrations
of TNFα, IL-6, and oxidative stress markers; 8-hydroxy-
2’-deoxyguanosine (8-OHdG) as a marker of DNA
damage and hexanoyl-lysine adduct (HEL) as a marker
of lipid peroxidation, and Cu,Zu-superoxide dismutase
(Cu,Zn-SOD) and melatonin, as antioxidants, in follicu-
lar fluids were measured using an ELISA kit or a radio-
immunoassay described below.





No. of patients 12 11
Age (yrs) 34.5 ± 3.4 33.5 ± 3.3 0.45
Gonadotropin dose (IU) 1502 ± 377 2209 ± 849a 0.037
Duration of COH (days) 8.6 ± 1.9 11.5 ± 3.4a 0.032
Estradiol (pg/ml) 1995 ± 1054 1280 ± 892 0.098
No. of follicles (≧15 mm) 7.1 ± 2.7 6.6 ± 3.8 0.79
No. of mature follicles (≧18 mm) 3.0 ± 2.0 3.2 ± 2.8 0.79
No. of oocytes retrieved 5.0 ± 2.9 5.7 ± 4.1 0.70
Fertilization rate (%) 51.7 (31/60) 39.7 (25/63) 0.21
Cases of IVF/ICSI 11 / 1 8 / 3
Cases of embryo transfer 8 8 0.79
No. of embryos transferred 1.2 ± 0.8 1.3 ± 1.0 0.74
Cases of 2–4 cell
embryo/blastcyst (cryopreserved)
4 (1) / 4 (1) 6 (0) / 2 (0)
Implantation rate (%) 8.3 (1/12) 21.4 (3/14) 0.35
Pregnancy rate (%) 8.3 (1/12) 27.3 (3/11) 0.23
Twenty-three infertile women with Stage III or IV endometriosis were recruited for
this study. Eleven patients received three courses of GnRHa (1.8 mg s.c. every
28 days), followed by a standard controlled ovarian hyperstimulation (COH) for
IVF-ET (ultralong group). Twelve patients received a standard COH with mid-luteal
phase GnRHa down-regulation (control group). Data are shown as the mean± SD.
a; significant difference (Fisher’s test or the Mann–Whitney U-test using the
Bonferroni correction).
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antioxidants in follicular fluids
Concentrations of TNFα and IL-6 were measured using
a Human TNFα ELISA kit and Human IL-6 ELISA kit
(Thermo Fisher Scientific Pierce Biotechnology, Rockford,
USA), respectively. Each sample of follicular fluid (50 μl)
was used for duplicate assay according to the assay proto-
col. The sensitivity of TNFα was 2 pg/ml, and the coeffi-
cients of variation (CV) for intra- and inter-assay were 4.5%
and 5.2%, respectively. The sensitivity of IL-6 was 1 pg/ml,
and the CV for intra- and inter-assay were <10%.
8-OHdG concentrations were measured using a New
8-OHdG Check ELISA (Japan Institute for the Control
of Aging, Nikken SEIL Co. Ltd., Shizuoka, Japan) as we
reported previously [26,27]. Each sample of follicular
fluid (50 μl) filtered using an ultrafilter (cut off molecular
weight 10 kDa) was used for duplicate assay. The sensitiv-
ity of 8-OHdG was 0.5 ng/ml, and the CV for intra- and
inter-assay were 5.5% and 6.1%, respectively.
HEL concentrations were measured using an ELISA kit
(Japan Institute for the Control of Aging) as we reported
previously [26,27]. Each sample of follicular fluid (50 μl)
was pretreated with chymotrypsin to perform proteolysis,
and filtered using an ultrafilter (cut off molecular weight
10 kDa) for duplicate assay. The minimal detectable con-
centration of HEL was estimated to be 2 nmol/L.
Cu,Zn-SOD concentrations were measured using a
Human Cu/Zn-superoxide dismutase ELISA kit (Northwest
Life Science Specialties, LLC, USA) as we reported previ-
ously [26,27]. Each sample of follicular fluid (20 μl) was
used for duplicate assay according to assay protocol. The
sensitivity of Cu,Zn-SOD was 0.04 ng/ml, and the CV for
intra- and inter-assay were 5.1% and 5.8%, respectively.
Intrafollicular concentrations of melatonin were mea-
sured by radioimmunoassay (RIA) as we reported previ-
ously [28]. Each sample of follicular fluid (500 μl) was
used for duplicate assay. The sensitivity of the assay
was 4.2 pg/ml, and the CV for intra- and inter-assay
were 6.3% and 4.9%, respectively.
Statistical analysis
Statistical analysis was carried out with SPSS for Windows
13.0. The Mann–Whitney U-test using the Bonferroni
correction and Fisher’s test were employed as appropriate.
Correlations were analyzed using Spearman’s rank correl-
ation coefficient. Differences were considered to be signifi-
cant if P <0.05.
Results
There was no significant difference in the mean age of
the patients between the two groups (Table 1). These
treatments resulted in the ultralong group receiving a
greater dose of gonadotropin and a longer duration of
ovarian stimulation (Table 1). The numbers of maturefollicles and retrieved oocytes, and fertilization rates
were not significantly different between the two groups
(Table 1). Embryo transfer was carried out in 8 of 12
cases in the control group and in 8 of 11 cases in the
ultralong group (Table 1). The implantation rate and
pregnancy rate were higher in the ultralong group
(21.4% and 27.3%, respectively) compared with the control
group (8.3% and 8.3%, respectively), but the differences
were not significant (Table 1).
TNFα concentrations in the follicular fluid were signifi-
cantly lower in the ultralong group (5.8 ± 3.2 pg/ml) than in
the control group (10.6 ± 3.2 pg/ml) (Figure 1). IL-6 was
not detected in the follicular fluid in either group. 8-OHdG
concentrations were slightly but significantly lower in the
ultralong group (5.7 ± 1.6 ng/ml) than in the control group
(6.6 ± 1.5 ng/ml), whereas the follicular HEL concentra-
tions were not significantly different (Figure 2). Melatonin
concentrations were significantly higher in the ultra-
long group (139.2 ± 45.7 pg/ml) than in the control
group (85.6 ± 27.4 pg/ml), while Cu,Zn-SOD concen-
trations were not significantly different between the
two groups (Figure 3).
The correlations between TNFα, 8-OHdG and mela-
tonin concentrations in the follicle were analyzed
using Spearman’s rank correlation coefficient. There were
slight positive correlations between TNFα and 8-OHdG
Figure 1 Tumor necrosis factor alpha (TNFα) concentrations in
follicular fluids. Twenty-three infertile women with Stage III or IV
endometriosis were recruited for this study. Eleven patients received three
courses of GnRHa (1.8 mg s.c. every 28 days), followed by a standard
controlled ovarian hyperstimulation (COH) for IVF-ET (ultralong group).
Twelve patients received a standard COH with mid-luteal phase GnRHa
down-regulation (control group). TNFα concentrations were measured in
the follicular fluid obtained at the time of oocyte retrieval. Values are
mean ± SD. Statistical analysis was employed with the Mann–Whitney
U-test using the Bonferroni correction.
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tween TNFα and melatonin (R = −0.0893, P = 0.6852)
and melatonin and 8-OHdG (R = −0.3976, P = 0.0602).
However, the trends were not statistically significant
because of a small sample size.
Discussion
The present result clearly showed that the concentra-
tions of a cytotoxic cytokine (TNFα) and oxidative stress
(8-OHdG) in follicular fluids were significantly lower in
the ultralong GnRHa therapy group than in the controlFigure 2 Concentrations of oxidative stress markers in follicular fluids
recruited for this study. Eleven patients received three courses of GnRHa (1
hyperstimulation (COH) for IVF-ET (ultralong group). Twelve patients receive
(control group). The levels of oxidative stress markers; 8-hydroxy-2’-deoxygu
adduct (HEL) as a marker of lipid peroxidation, were measured in the follicu
mean ± SD. Statistical analysis was employed with the Mann–Whitney U-tegroup, suggesting a potential mechanism that additional
GnRHa treatment before IVF-ET improves the pregnancy
outcome of IVF-ET by reducing the detrimental effects of
cytotoxic cytokines and oxidative stress in the peritoneal
environment or implantation environment in patients
with endometriosis. TNFα and oxidative stress in ovarian
follicles not only damage oocytes and embryos leading
to the impaired fertilization, but also impair endometrial
receptivity leading to implantation failure in patients with
endometriosis [10-14].
Although ultralong GnRHa therapy reduced the con-
centrations of TNFα and oxidative stress markers in
ovarian follicles, it is unclear whether it also reduced
them in the peritoneal cavity and in the endometrium.
Since it is reported that the cytokine levels were de-
creased by GnRHa treatment in the peritoneal cavity as
well as in the ovary [29,30], there is a possibility that
the hostile environment of the peritoneal cavity and
endometrial cavity was improved by ultralong GnRHa
therapy in this study. Therefore, we hypothesize that
the decrease in TNFα and oxidative stress by ultralong
GnRHa therapy may have contributed to the improve-
ment of implantation rate and pregnancy rate.
Interestingly, ultralong GnRHa therapy increased the
melatonin concentrations in the follicular fluid (Figure 3).
Melatonin is a hormone secreted by the pineal gland,
and regulates a variety of central and peripheral actions
related to circadian rhythms and reproduction. Melatonin
is a powerful free radical scavenger and a broad-spectrum
antioxidant [31,32]. We previously demonstrated that
melatonin is present in human ovarian follicles and
that its concentration increases during follicular growth
[18-20]. We also reported that melatonin is taken up
into the follicular fluid from the blood, and that it pro-
tects oocytes from ROS within the follicle during ovulation. Twenty-three infertile women with Stage III or IV endometriosis were
.8 mg s.c. every 28 days), followed by a standard controlled ovarian
d a standard COH with mid-luteal phase GnRHa down-regulation
anosine (8-OHdG) as a marker of DNA damage and hexanoyl-lysine
lar fluid obtained at the time of oocyte retrieval. Values are
st using the Bonferroni correction.
Figure 3 Concentrations of antioxidants in follicular fluids. Twenty-three infertile women with Stage III or IV endometriosis were recruited for
this study. Eleven patients received three courses of GnRHa (1.8 mg s.c. every 28 days), followed by a standard controlled ovarian hyperstimulation
(COH) for IVF-ET (ultralong group). Twelve patients received a standard COH with mid-luteal phase GnRHa down-regulation (control group). The
levels of Cu,Zu-superoxide dismutase (Cu,Zn-SOD) and melatonin, as antioxidants, were measured in the follicular fluid obtained at the time of
oocyte retrieval. Values are mean ± SD. Statistical analysis was employed with the Mann–Whitney U-test using the Bonferroni correction.
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oxidant activities by melatonin in follicular fluids by
ultralong GnRHa therapy may also have contributed to
the improvement of implantation rate and pregnancy
rate. The mechanism by which ultralong GnRHa ther-
apy increases the melatonin concentration in the follicle
is unclear. We speculate that ultralong GnRHa therapy
may have improved the function of the follicle by redu-
cing inflammation of the ovary so that the follicle can
effectively take up melatonin.
It is unclear how TNFα, oxidative stress, and melatonin
interacts each other. There were slight positive correlations
between TNFα and 8-OHdG, and negative correlations be-
tween TNFα and melatonin, and melatonin and 8-OHdG,
although the trends were not statistically significant. These
results may suggest that TNFα induces oxidative stress
and decreases melatonin levels in the follicle. In other
words, the reduced TNFα by ultralong GnRHa therapy
may be responsible for the decrease in oxidative stress and
the increase in melatonin in the follicle.
On the other hand, as a demerit of the ultralong
GnRHa therapy, our results showed a need for greater
gonadotropin doses and longer COH days than in
patients who received a standard mid-luteal GnRHa
down-regulation protocol, which is also consistent
with previous reports [34].
Unfortunately, the present study did not clearly show
that ultralong GnRHa therapy improves the fertility of
patients with endometriosis. This may be due to the
small sample size of this study. A large-scale randomized
controlled trial will be necessary to evaluate the efficacy
of ultralong GnRHa therapy on pregnancy outcome in
patients with endometriosis. It is also interesting to in-
vestigate whether there are any differences in follicular
levels of TNFα, 8-OHdG, and melatonin between thefollicles containing fertilized and unfertilized, implanted and
non-implanted, or pregnant and non-pregnant oocytes.
Conclusions
This study suggested a possible mechanism of ultralong
GnRHa therapy to improve the pregnancy outcome of
IVF-ET, which is the reduction of the detrimental ef-
fect of cytokines and oxidative stress in the peritoneal
environment or implantation environment in patients
with endometriosis.
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